Opening the door to innovation.
Open innovation is the new buzz, with initiatives popping up left and right. Here, we give a personal perspective on a very successful, knowledge-driven innovation initiated in an academia- industry alliance, which culminated in technology platforms that enable the generation of therapeutic antibodies with novel properties. To start, we provide a general background on open innovation in the drug development field.
Genmab; Utrecht, The Netherlands.
Janine
J
Schuurman
Genmab; Utrecht, The Netherlands.
Yvo F
YF
Graus
Genmab; Utrecht, The Netherlands.
Aran F
AF
Labrijn
Genmab; Utrecht, The Netherlands.
Sigrid
S
Ruuls
Genmab; Utrecht, The Netherlands.
Paul W H I
PW
Parren
D000818:Animals; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D017277:Drug Approval; D015195:Drug Design; D006801:Humans
D000911:Antibodies, Monoclonal
Duobody technology; Fab-arm exchange; Open innovation; Technology platform; bispecific antibodies; drug development; immunotherapy